相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phosphodiesterase 4 inhibitors in diabetic nephropathy
Mitsugi Ookawara et al.
CELLULAR SIGNALLING (2022)
Clinical Implication of Phosphodiesterase-4-Inhibition
Martin Alexander Schick et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-131 pathway: therapeutic role of roflumilast
Xiang Tao et al.
PHARMACOLOGICAL RESEARCH (2022)
Combined Endoscopic and Radiologic Healing Is Associated With a Better Prognosis Than Endoscopic Healing Only in Patients With Crohn's Disease Receiving Anti-TNF Therapy
Kyunghwan Oh et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2022)
The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs
Hoang Oanh Nguyen et al.
FRONTIERS IN IMMUNOLOGY (2022)
Novel Liposomal Rolipram Formulation for Clinical Application to Reduce Emesis
Leila Gobejishvili et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2022)
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking
Claire Lugnier et al.
BIOCHEMICAL PHARMACOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Therapeutic potential of phosphodiesterase inhibitors in the treatment of osteoporosis: Scopes for therapeutic repurposing and discovery of new oral osteoanabolic drugs
Konica Porwal et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases
Andrea Picchianti-Diamanti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19
Sugin Lal S. Jabaris et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2021)
Pyrrolo[2,3-b]quinoxalines in attenuating cytokine storm in COVID-19: their sonochemical synthesis and in silico / in vitro assessment
Raviteja Chemboli et al.
JOURNAL OF MOLECULAR STRUCTURE (2021)
Rolipram Prevents the Formation of Abdominal Aortic Aneurysm (AAA) in Mice: PDE4B as a Target in AAA
Saray Varona et al.
ANTIOXIDANTS (2021)
Roflumilast Suppresses Adipogenic Differentiation via AMPK Mediated Pathway
Wan Xu et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
cAMP Compartmentalization in Cerebrovascular Endothelial Cells: New Therapeutic Opportunities in Alzheimer's Disease
Dolores Vina et al.
CELLS (2021)
Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?
Claire Lugnier et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Inhibition of PDE4 protects neurons against oxygen-glucose deprivation-induced endoplasmic reticulum stress through activation of the Nrf-2/HO-1 pathway
Bingtian Xu et al.
REDOX BIOLOGY (2020)
PDE4 subtypes in cancer
Samuel Hsien Lai et al.
ONCOGENE (2020)
Fibroblast growth factor 23 decreases PDE4 expression in heart increasing the risk of cardiac arrhythmia; Klotho opposes these effects
Marta Lindner et al.
BASIC RESEARCH IN CARDIOLOGY (2020)
The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice
Hao Wang et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2020)
Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19
Maria Dalamaga et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2020)
Creating a potential diagnostic for prostate cancer risk stratification (InformMDx™) by translating novel scientific discoveries concerning cAMP degrading phosphodiesterase-4D7 (PDE4D7)
Dave J. P. Henderson et al.
CLINICAL SCIENCE (2019)
PDE4 and Epac1 Synergistically Promote Rectal Carcinoma via the cAMP Pathway
Xiangyu Kong et al.
ANALYTICAL CELLULAR PATHOLOGY (2019)
Inhibition of phosphodiesterase 4D decreases the malignant properties of DLD-1 colorectal cancer cells by repressing the AKT/mTOR/Myc signaling pathway
Dong Uk Kim et al.
ONCOLOGY LETTERS (2019)
Phosphodiesterase 4 Inhibition as a Therapeutic Target for Alcoholic Liver Disease: From Bedside to Bench
Walter E. Rodriguez et al.
HEPATOLOGY (2019)
Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss - results of an exploratory study
Ijeoma M. Muo et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2019)
Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases
Faisa Omar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Identification of diagnostic markers for major depressive disorder by cross-validation of data from whole blood samples
Huimei Wang et al.
PEERJ (2019)
Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
George S. Baillie et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches
Amy J. Tibbo et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2019)
The Endocrine Function of the Heart: Physiology and Involvements of Natriuretic Peptides and Cyclic Nucleotide Phosphodiesterases in Heart Failure
Claire Lugnier et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Phosphodiesterase Type 4 Inhibition in CNS Diseases
Arjan Blokland et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
Phosphodiesterase-4 inhibition reduces ECLS-induced vascular permeability and improves microcirculation in a rodent model of extracorporeal resuscitation
Jakob Wollborn et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2019)
Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease
Luisa Vonghia et al.
FRONTIERS IN IMMUNOLOGY (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Identification of a PDE4-Specific Pocket for the Design of Selective Inhibitors
Xiaoqing Feng et al.
BIOCHEMISTRY (2018)
PDE4 and mAKAPβ are nodal organizers of β2-ARs nuclear PKA signalling in cardiacmyocytes
Ibrahim Bedioune et al.
CARDIOVASCULAR RESEARCH (2018)
A comprehensive review and update on Crohn's disease
Mahesh Gajendran et al.
DM DISEASE-A-MONTH (2018)
Inhibitors of phosphodiesterase as cancer therapeutics
Ting Peng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
PRDM16 Gene Polymorphism Is Associated with Obesity and Blood Lipids Profiles in Saudi Population
Aishah AlAmrani et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice
Chong Zhang et al.
NEUROPSYCHOPHARMACOLOGY (2018)
The conserved protective cyclic AMP-phosphodiesterase function PDE4B is expressed in the adenoma and adjacent normal colonic epithelium of mammals and silenced in colorectal cancer
Jennifer K. Pleiman et al.
PLOS GENETICS (2018)
Compound D159687, a phosphodiesterase 4D inhibitor, induces weight and fat mass loss in aged mice without changing lean mass, physical and cognitive function
Ijeoma M. Muo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Advances in osteoporosis from 1970 to 2018
J. Christopher Gallagher
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2018)
Prevalence of osteoporosis with the World Health Organization diagnostic criteria in the Eastern Mediterranean Region: a systematic review and meta-analysis
Mohammad Zamani et al.
ARCHIVES OF OSTEOPOROSIS (2018)
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update
Shamir Geller et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
β-Cell Autophagy in Diabetes Pathogenesis
Michelle R. Marasco et al.
ENDOCRINOLOGY (2018)
Functional Significance of the Adcy10-Dependent Intracellular cAMP Compartments
Sofya Pozdniakova et al.
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE (2018)
PDE4-Mediated cAMP Signalling
Bracy A. Fertig et al.
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE (2018)
Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners
Kirsty F. Houslay et al.
BIOCHEMICAL JOURNAL (2017)
Effects of cyclic nucleotide phosphodiesterases (PDEs) on mitochondrial skeletal muscle functions
Liliane Tetsi et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue
Marco Spadaccini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Regulatory T Cells Contribute to HIV-1 Reservoir Persistence in CD4+ T Cells Through Cyclic Adenosine Monophosphate-Dependent Mechanisms in Humanized Mice In Vivo
Guangming Li et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
The risk of melanoma and hematologic cancers in patients with psoriasis
Shivani P. Reddy et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases
Carmen W. Dessauer et al.
PHARMACOLOGICAL REVIEWS (2017)
Roflumilast restores cAMP/PKA/CREB signaling axis for FtMt-mediated tumor inhibition of ovarian cancer
Shipeng Gong et al.
ONCOTARGET (2017)
Altered phosphorylation, electrophysiology, and behavior on attenuation of PDE4B action in hippocampus
Susan L. Campbell et al.
BMC NEUROSCIENCE (2017)
Evaluation of glycated albumin (GA) and GA/HbA1c ratio for diagnosis of diabetes and glycemic control: A comprehensive review
Sara Yazdanpanah et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2017)
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
K. Ogurtsova et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Pharmacokinetic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK-648 in Type 2 Diabetes: Early Translational Approaches for Human Dose Prediction
N. Plock et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2017)
The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism
Julia Moellmann et al.
DIABETES OBESITY & METABOLISM (2017)
A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma
A. N. Suhasini et al.
LEUKEMIA (2016)
Protein-protein interactions of PDE4 family members - Functions, interactions and therapeutic value
Enno Klussmann
CELLULAR SIGNALLING (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
The analgesic effect of rolipram is associated with the inhibition of the activation of the spinal astrocytic JNK/CCL2 pathway in bone cancer pain
Chi-Hua Guo et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis
Diana V. Avila et al.
JOURNAL OF PATHOLOGY (2016)
UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy
Li Wang et al.
CELLULAR SIGNALLING (2015)
Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition
Abdurazzag Abusnina et al.
THROMBOSIS AND HAEMOSTASIS (2015)
Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study
Mojca Jensterle et al.
JOURNAL OF OVARIAN RESEARCH (2015)
Phosphodiesterase-4D Knock-down in the Prefrontal Cortex Alleviates Chronic Unpredictable Stress-Induced Depressive-Like Behaviors and Memory Deficits in Mice
Zhen-Zhen Wang et al.
SCIENTIFIC REPORTS (2015)
Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets
F. Ahmad et al.
ORAL DISEASES (2015)
Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4
F. Hubert et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis
Vlad Ratziu et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Advances in targeting cyclic nucleotide phosphodiesterases
Donald H. Maurice et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
PDE4 in the human heart - major player or little helper?
Thomas Eschenhagen
BRITISH JOURNAL OF PHARMACOLOGY (2013)
β1-adrenergic receptor antagonists signal via PDE4 translocation
Wito Richter et al.
EMBO REPORTS (2013)
Roflumilast Inhibits Respiratory Syncytial Virus Infection in Human Differentiated Bronchial Epithelial Cells
Manuel Mata et al.
PLOS ONE (2013)
Inhibition of phosphodiesterase 4 modulates cytokine induction from toll like receptor activated, but not rhinovirus infected, primary human airway smooth muscle
David Van Ly et al.
RESPIRATORY RESEARCH (2013)
Rolipram Attenuates Bile Duct Ligation-Induced Liver Injury in Rats: A Potential Pathogenic Role of PDE4
Leila Gobejishvili et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
PDE3 and PDE4 Isozyme-Selective Inhibitors Are Both Required for Synergistic Activation of Brown Adipose Tissues
Stephen M. Kraynik et al.
MOLECULAR PHARMACOLOGY (2013)
Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments
Therese Keravis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Role of phosphodiesterases in the shaping of sub-plasma-membrane cAMP oscillations and pulsatile insulin secretion
Geng Tian et al.
JOURNAL OF CELL SCIENCE (2012)
Resveratrol as a calorie restriction mimetic: therapeutic implications
Jay H. Chung et al.
TRENDS IN CELL BIOLOGY (2012)
Conserved expression and functions of PDE4 in rodent and human heart
Wito Richter et al.
BASIC RESEARCH IN CARDIOLOGY (2011)
Phosphodiesterase 4D Regulates Baseline Sarcoplasmic Reticulum Ca2+ Release and Cardiac Contractility, Independently of L-Type Ca2+ Current
Sanja Beca et al.
CIRCULATION RESEARCH (2011)
PDE inhibitors: a new approach to treat metabolic syndrome?
Claire Lugnier
CURRENT OPINION IN PHARMACOLOGY (2011)
Phosphodiesterase 4B in the cardiac L-type Ca2+ channel complex regulates Ca2+ current and protects against ventricular arrhythmias in mice
Jerome Leroy et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Enhanced long-term depression and impaired reversal learning in phosphodiesterase 4B-knockout (PDE4B-/-) mice
Kris Rutten et al.
NEUROPHARMACOLOGY (2011)
Inhibition of phosphodiesterase-4 decreases ethanol intake in mice
Wei Hu et al.
PSYCHOPHARMACOLOGY (2011)
Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity
B. Omar et al.
NUTRITION & DIABETES (2011)
Cyclic AMP Suppression Is Sufficient to Induce Gliomagenesis in a Mouse Model of Neurofibromatosis-1
Nicole M. Warrington et al.
CANCER RESEARCH (2010)
Cyclic Nucleotide Phosphodiesterases (PDE) and Peptide Motifs
Therese Keravis et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Cyclic AMP Phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a Vascular Endothelial Cadherin (VE-Cad)-based Signaling Complex and Controls cAMP-mediated Vascular Permeability
Sarah N. Rampersad et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety
Alex B. Burgin et al.
NATURE BIOTECHNOLOGY (2010)
Concerted Regulation of cGMP and cAMP Phosphodiesterases in Early Cardiac Hypertrophy Induced by Angiotensin II
Walid Mokni et al.
PLOS ONE (2010)
The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
Armin Hatzelmann et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2010)
Decreased Expression and Activity of cAMP Phosphodiesterases in Cardiac Hypertrophy and Its Impact on β-Adrenergic cAMP Signals
Aniella Abi-Gerges et al.
CIRCULATION RESEARCH (2009)
Reduced Adiposity and High-Fat Diet-Induced Adipose Inflammation in Mice Deficient for Phosphodiesterase 4B
Ren Zhang et al.
ENDOCRINOLOGY (2009)
Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure
David E. Lanfear et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832/13) cells and rat islets
Deena Waddleton et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Phosphodiesterases in the CNS: targets for drug development
Frank S. Menniti et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats
HT Zhang et al.
PSYCHOPHARMACOLOGY (2006)
Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis
S Videla et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Phosphodiesterase-4 as a therapeutic target
MD Houslay et al.
DRUG DISCOVERY TODAY (2005)
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias
SE Lehnart et al.
CELL (2005)
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
K Kuba et al.
NATURE MEDICINE (2005)
Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells
M Ahlström et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4
L Favot et al.
THROMBOSIS AND HAEMOSTASIS (2004)
The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases
W Richter et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells - Cross-talk between the cAMP and the retinoic acid signaling pathways
E Parrella et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors
L Favot et al.
THROMBOSIS AND HAEMOSTASIS (2003)
Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition
M Narita et al.
ANTI-CANCER DRUGS (2003)
Myomegalin is a novel protein of the Golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase
I Verde et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
OPC-compounds prevent oxidant-induced carbonylation and depolymerization of the F-actin cytoskeleton and intestinal barrier hyperpermeability
A Banan et al.
FREE RADICAL BIOLOGY AND MEDICINE (2001)
Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice
T Kinoshita et al.
BONE (2000)
Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases
GS Baillie et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Infection of CD4+ memory T cells by HIV-1 requires expression of phosphodiesterase 4
Y Sun et al.
JOURNAL OF IMMUNOLOGY (2000)
Cyclic nucleotide hydrolysis in bovine aortic endothelial cells in culture: Differential regulation in cobblestone and spindle phenotypes
T Keravis et al.
JOURNAL OF VASCULAR RESEARCH (2000)
分享论文
